![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260924_Elevar_Therapeutics_Therapeutic_Indications-768x384.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Elevar Therapeutics<\/p>\n Event Type<\/strong><\/p>\n FDA Approval<\/p>\n Modality<\/strong><\/p>\n Small Molecule (Selective FGFR2 Kinase Inhibitor)<\/p>\n Asset<\/strong><\/p>\n Lirafugratinib (Lyrfigtu)<\/p>\n Target<\/strong><\/p>\n FGFR2<\/p>\n Disease Area<\/strong><\/p>\n FGFR2 Fusion\/Rearrangement Cholangiocarcinoma<\/p>\n The FDA approved lirafugratinib, branded Lyrfigtu, for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement. In the single-arm REFOCUS study of 116 FGFR-inhibitor-naive patients, independently reviewed objective response rate was 46% and median duration of response was 11.8 months.<\/p>\n The oral 70 mg once-daily therapy is a selective FGFR2 kinase inhibitor. Approval used the Real-Time Oncology Review and Assessment Aid programs and followed priority review, breakthrough-therapy and orphan-drug designations. The indication requires molecular selection and prior systemic treatment.<\/p>\n The label warns about ocular toxicity, hyperphosphatemia with soft-tissue mineralization, and embryo-fetal toxicity. Across the broader safety population, retinal pigment epithelial detachment occurred in 31%, including 1.8% Grade 3 events. U.S. commercial availability is expected in the fourth quarter of 2026, according to the sponsor.<\/p>\n Interpretation one is that selective FGFR2 inhibition adds another active option with a substantial response rate and near-one-year median response duration. Molecular specificity may reduce some FGFR1-mediated effects, but the approved evidence is nonrandomized and does not establish superior efficacy or tolerability against pemigatinib, futibatinib or other available FGFR inhibitors.<\/p>\n Interpretation two is that differentiation may depend on resistance coverage and treatment sequencing rather than first-response rate alone. Acquired kinase-domain mutations, ocular monitoring, phosphate management, testing access and payer positioning will shape use. Prospective comparative evidence, activity after prior FGFR inhibition and real-world discontinuation rates would upgrade the competitive thesis; rapid resistance or higher-than-expected ocular toxicity would downgrade it.<\/p>\n Elevar Therapeutics is majority owned by South Korea’s HLB. Lirafugratinib was previously known as RLY-4008 and selectively inhibits FGFR2. FGFR2 fusions activate growth signaling in a molecular subset of intrahepatic cholangiocarcinoma, creating a targetable dependency after first-line therapy.<\/p>\n The approval is a clear positive regulatory signal and expands precision treatment in a rare biliary cancer. It does not establish best-in-class status. Commercial and clinical differentiation will depend on molecular testing, tolerability, resistance mutations and evidence in patients previously exposed to another FGFR inhibitor.<\/p>\n Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: high based on the FDA approval notice and disclosed label data. Confidence in Interpretation: moderate-high for regulatory significance and moderate for competitive uptake.<\/p>\n","protected":false},"excerpt":{"rendered":" The FDA approved lirafugratinib, branded Lyrfigtu, for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement. In the single-arm REFOCUS study of 116 FGFR-inhibitor-naive patients, independently reviewed…<\/p>\n","protected":false},"author":1,"featured_media":3443,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,3],"tags":[473,172,858],"class_list":["post-3426","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-therapeutic-indication","tag-cholangiocarcinoma","tag-elevar-therapeutics","tag-fgfr2"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3426"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3426\/revisions"}],"predecessor-version":[{"id":3448,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3426\/revisions\/3448"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3443"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n